Psilocybin
Properties
- Molecular formula
- C12H17N2O4P
- Molar mass
- 284.25 g/mol
- Exact mass
- 284.0926 Da
- logP
- 1.74Crippen estimate
- Polar surface area
- 85.8 Ų
- H-bond donors / acceptors
- 3 / 3
- Rotatable bonds
- 5
Psilocybin — prodrug of psilocin, active in psilocybe mushrooms and the leading psychedelic candidate for FDA approval. Compass Pathways hit its primary endpoint in two Phase-3 trials of synthetic COMP360 for treatment-resistant depression: COMP005 (June 2025, single 25 mg dose, MADRS -3.6 vs placebo, p<0.001) and COMP006 (February 2026, two 25 mg doses, -3.8 vs 1 mg active comparator at Week 6, 39% achieving meaningful response). In April 2026 the FDA granted COMP360 a rolling NDA review and a Commissioner's National Priority Voucher — a 1-2 month review-clock pathway that could deliver the first FDA-approved psychedelic by 2027.
Hazards
No GHS classification is on file for this compound. That is not evidence that it is harmless. Search the SDS library
Identifiers
520-52-5CN(C)CCc1c[nH]c2cccc(OP(O)(O)=O)c12QVDSEJDULKLHCG-UHFFFAOYSA-OInChI=1S/C12H17N2O4P/c1-14(2)7-6-9-8-13-10-4-3-5-11(12(9)10)18-19(15,16)17/h3-5,8,13H,6-7H2,1-2H3,(H2,15,16,17)/p+1Weigh it out
Type any one amount. The others follow from the molar mass.
Names and synonyms
1 names
- [3-(2-Dimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate
Work with Psilocybin
Similar compounds
Tanimoto similarity of circular fingerprints over the whole catalogue. All similar compounds